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PGC-1alphaHuntington's disease (HD) is a prototypical neurodegenerative disease in which there is selective neuronal
degeneration, which leads to progressive disability, manifesting itself as a movement disorder, with both psy-
chiatric and cognitive impairment. The disease is caused by a cytosine–adenine–guanine (CAG) repeat ex-
pansion in the huntingtin gene, which causes an expanded polyglutamine repeat in the huntingtin protein,
resulting in a protein with a novel gain of function. The mutant huntingtin protein causes neuronal dysfunc-
tion and eventual cell death in which transcriptional impairment, excitotoxicity, oxidative damage, inﬂam-
mation, apoptosis and mitochondrial dysfunction are all implicated. A critical transcriptional impairment
may be impaired expression and function of peroxisome proliferator-activated receptor gamma
coactivator-1α (PGC-1α), a master co-regulator of mitochondrial biogenesis and expression of antioxidant
enzymes. A deﬁciency of PGC-1α leads to increased vulnerability to oxidative stress and to striatal degener-
ation. The extent and severity of the oxidative damage in HD are features well recognized but perhaps under-
appreciated. Oxidative damage occurs to lipids, proteins and deoxyribonucleic acid (DNA), and it has been
suggested that the latter may contribute to CAG repeat expansion during DNA repair [1]. A marked elevation
of oxidized DNA bases occurs in patients' plasma, which may provide a biomarker of disease progression. An-
tioxidants are effective in slowing disease progression in transgenic mouse models of HD, and show promise
in human clinical trials. Strategies to transcriptionally increase expression of antioxidant enzymes by modu-
lating the Nrf-2/ARE pathway, or by increasing expression of PGC-1α hold great promise for developing new
treatments to slow or halt the progression of HD. This article is part of a Special Issue entitled: Antioxidants
and Antioxidant Treatment in Disease.
Published by Elsevier B.V.1. Introduction
1.1. Huntington's disease (HD)
Named after George Huntington, who provided a classic account
of the condition in 1872, Huntington's disease (HD), is a fatal, domi-
nantly inherited progressive neurodegenerative disorder, caused by
a variable length CAG repeat expansion in the huntingtin (HTT)
gene that translates into an abnormally long polyglutamine repeat
in the mutant huntingtin (mhtt) protein. The disease is characterized
by motor and cognitive impairment, a variable degree of personality
change, and psychiatric illness [2,3]. In addition, metabolic abnormal-
ities such as wasting and altered energy expenditure are increasingly
recognized as clinical hallmarks of the disease. There is progressive
disability, and death usually occurs 15 to 20 years after onset. Thereants and Antioxidant Treatment
nd Neuroscience,WeillMedical
0, New York, NY 10065, USA.
beal@med.cornell.edu
.V.are no currently available treatments to delay disease onset or retard
its progression, and the focus of medical care is limited to symptom
management and maximizing function. Disease manifestations can
begin at any time in life; the most common age range of onset is be-
tween 30 and 50 years old, although it occurs in children and the el-
derly as well [4]. The number of CAG repeats in the HTT gene is the
main predictor of the age of disease-onset, but the remaining varia-
tion is strongly heritable. Patients with HD have CAG repeat lengths
above 36, with variable penetrance of repeat lengths 36–39 and com-
plete penetrance above 39 repeats; longer repeat lengths (>60) have
been associated with juvenile-onset HD [3]. Individuals at risk of
inheriting the expanded CAG nucleotide can be identiﬁed before clin-
ical onset by predictive genetic testing [5]. Although the length of
CAG repeat can be used for predicting age of onset, the CAG repeat
length seems to contribute less to the rate of progression and under-
standing the determinants of rate of progression, could help in ﬁnd-
ing means for therapeutic intervention [6].
The motor abnormality originates from dysfunction of the control
of involuntary movements in a brain region known as the striatum,
and is manifested as a hallmark feature of uncontrollable dance-like
movements (chorea). Neuropathological analysis of HD brains reveals
preferential and progressive neuronal loss of the GABAergic medium-
sized spiny neurons (MSNs) in the striatum, although cortical atrophy
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campus, and amygdala, also occurs as the disease progresses [3,7].
The cortical atrophy progresses from the motorsensory cortex to the
occipital, parietal and limbic cortices [8]. Atrophy of the basal ganglia,
thinning of the cortex and atrophy of the whole brain precede the
overt onset of clinical symptoms by years. The MSNs are the primary
neuronal type of the caudate putamen, constituting 90% of the total
population of neurons. In HD, there is clear selective vulnerability of
MSNs, and yet some neurons survive, despite the expression of
mhtt protein and development of aggregates [9,10]. NADPH diapho-
rase/NO synthetase interneurons and cholinergic interneurons are
spared, and calretinin interneurons are partially spared [11,12]. In
HD, the earliest cell loss appears in the GABA/enkephalin neurons
projecting to the lateral globus pallidus (the indirect motor pathway)
and is thought to underlie the development of chorea. Later, the
GABA/substance P/dynorphin cells projecting to the substantia nigra
pars reticulata and the medial globus pallidus (direct pathway) are
affected, leading to motor incoordination, increasedmuscle tone, dys-
tonia, and abnormal eye movements [10,13].
1.2. Preferential vulnerability of striatal neurons in the context of
huntingtin
In comparison to other protein aggregation disorders, the prefer-
ential striatal degeneration appears to be intimately connected to
huntingtin's protein context, but how mhtt elicits this effect remains
unknown. The htt protein is a large protein (~3300 amino acids) lo-
cated mostly in the cytoplasm of the cell and is ubiquitously
expressed throughout the body, with the highest expression in
brain and testes. The functions of htt protein have not been fully elu-
cidated yet, although it has been shown that htt is required for neuro-
genesis, and the HTT gene appears to be essential for survival [14–16].
Wild-type htt is involved in developmental apoptosis and potential
roles in vesicle trafﬁcking, RNA biogenesis, endocytosis, mitosis and
intracellular signaling have been inferred by its propensity for co-
localization with synaptic vesicles, microtubules, spindle poles and
the postsynaptic density [17–23]. Mutant htt toxicity can be attribut-
ed mainly to a toxic gain of a novel function (transcriptional modula-
tion, protein aggregation and excitotoxicity), and partly to a loss of
wild-type htt function (impaired BDNF gene expression and vesicle
trafﬁcking). Homozygous mhtt mice develop normally, whereas ex-
pression of a single allele of the mutant gene is sufﬁcient to rescue
htt-null mice from death in utero [17]. Similar to wild-type htt, mhtt
is also ubiquitously expressed, with no overt selectivity for the brain
regions targeted by the disease process, suggesting that another
property of mhtt, or neurons within these regions, confers vulnerabil-
ity to mhtt toxicity.
At any given time, ~5% of the cell's htt is found in the nucleus, sug-
gesting that it shuttles between the nucleus and the cytoplasm [24].
The N-terminal 17-amino acid sequence of htt has been suggested
to act as a nuclear export signal owing to its binding to the nuclear ex-
porter translocated promoter region (Tpr). Expansion of the polyglu-
tamine (polyQ) repeat interferes with this interaction causing
accumulation of mhtt in the nucleus [25]. It has been shown that in-
creasing nuclear localization of mhtt increases its cytotoxicity, indi-
cating that a nuclear action of mhtt is required for it to induce
toxicity [26]. The presence of htt aggregates, predominantly com-
posed of N-terminal fragments of polyQ expanded htt, in the nucleus
and cytoplasm of affected neurons, both in patient brains and in
model systems, are a pathological hallmark of HD; suggesting that
proteolytic cleavage of htt plays a key role in pathogenesis [27,28].
In vitro and animal studies show that polyQ induced toxicity is exac-
erbated by protein truncation. N-terminal mhtt fragments are sufﬁ-
cient to produce HD-like abnormal clinical syndromes in animal
models [29] and truncated mhtt, in contrast to full-length mhtt, in-
duces apoptosis [30]. Inhibition of mutant htt cleavage reducestoxicity, indicating a causative role for htt proteolysis in HD patho-
genesis [31,32].
Based on the ﬁndings that htt fragments are most abundant in cor-
tical projection neurons, it was proposed that accumulation of mhtt
fragments may contribute to the selective corticostriatal dysfunction
which occurs in HD pathogenesis [33]. The fragmented htt with the
expanded polyQ domain, has an increased propensity to bind to
other proteins including, various transcription factors, repressors
and co-factors; proapoptotic caspases, calmodulins and transglutami-
nases [reviewed in 34]. The events that are caused directly by mhtt or
its fragments trigger cascades of both damaging and compensatory
molecular processes and genetic programs. These ultimately lead to
increasingly dysfunctional neurons that are susceptible to more ge-
neric stresses (Fig. 1). These stresses include oxidative injury, excito-
toxic stress, disordered neurophysiology {such as increased activity of
N-methyl-D-aspartate (NMDA) glutamate receptors}, expression of
potentiating inﬂammatory signals, pro-apoptotic signals that activate
caspase 8 and caspase 3, malfunctioning proteolysis, increased trans-
glutaminase activity and energy depletion.
Many studies have provided evidence for a link between mutant
huntingtin protein, and mitochondrial abnormalities—and subsequent
impaired mitochondrial function and dynamics—that could ultimately
lead to neuronal damage and degeneration in affected brain regions
of patients with HD [35–40]. Mitochondrial dysfunction in HD may
occur through aberrant transcriptional regulation, as mhtt binds to
several transcriptional regulators and interferes with their function.
In particular, expression of peroxisome proliferator-activated receptor
gamma coactivator-1α (PGC-1α), a master transcriptional co-
regulator of mitochondrial biogenesis and antioxidant enzymes, is
reduced in HD, which may contribute to mitochondrial impairment
[41–46]. We showed that there are pathologic grade-dependent reduc-
tions in numbers of striatal mitochondria that correlate with reductions
in PGC-1α [36]. In addition, a direct interaction of mhtt with mitochon-
dria or with various protein complexes may play an important role in
pathogenesis, by regulating mitochondrial ﬁssion–fusion events, and
mitochondrial trafﬁcking along axons and dendrites [47]. Expression
of mhtt causes abnormal mitochondrial ultrastructure, impaired calci-
um buffering, bioenergetic defects and mitochondrial DNA deletions,
all of whichmay be a consequence of a failure tomaintain a balance be-
tween mitochondrial ﬁssion and fusion [37,38]. Mitochondrial dynam-
ics are abnormal in patients with HD as compared with healthy
controls; there is an increased expression of mitochondrial ﬁssion pro-
teins (Drp1 and Fis1), and of the mitochondrial matrix protein CypD;
decreased levels of mitochondrial fusion proteins (Mfn1, Mfn2, Opa1
and Tomm40) occur in HD patients, and levels of CypD increase with
HD progression [36,40]. Evidence of oxidative DNA damage (increased
levels of the oxidative stress biomarker 8-hydroxy-2-deoxyguanosine)
and loss of mitochondrial function (reduced levels of the electron
transport proteins cytochrome b and cytochrome c oxidase 1) were
found in individuals with HD, and these patients also exhibited mark-
edly increased levels of mhtt oligomers in the cerebral cortex. Impor-
tantly, immunolabelling of brain samples showed the presence of
mhtt oligomers in the nuclei of neurons and mitochondria of patients
with HD. HD medium spiny neurons show reduced numbers of mito-
chondria due to reduced levels of PGC-1α [36]. Medium spiny neurons
also have long projections as compared to interneurons, which may
make them preferentially vulnerable to increased mitochondrial ﬁssion
[36,40].
1.3. Reactive oxygen species (ROS)
Free radicals are molecules or molecular fragments containing one
or more unpaired electrons in their atomic or molecular orbitals [48].
The unpaired electron(s) usually provide a large amount of reactivity
to the free radical. Radicals derived from oxygen represent the most
important class of radical species generated in living systems [49].
Fig. 1. (Top) Vicious cycle induced by mutant htt (mhtt): mhtt causes damage to mitochondria, which then produce harmful reactive oxygen species (ROS), which in turn damage
more mitochondria. Mitochondria in mutant cells are thus particularly vulnerable to stresses such as respiratory chain complex inhibitors, Ca+2 and ROS. (Center) mhtt binds more
tightly to the mitochondrial ﬁssion protein Drp-1, causing mitochondrial fragmentation. mhtt also impairs mitochondrial movement thus reducing ATP at nerve terminals. (Bot-
tom) mhtt interferes with the function and/or transcription of PGC-1α, thus resulting in downregulation of PGC-1α target genes such as those involved in mitochondrial biogenesis
and antioxidant defense.
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and is itself a radical. Oxygen free radicals, frequently referred to as
reactive oxygen species (ROS), are normally generated during reac-
tions of cellular metabolism.
ROS include superoxide, hydroxyl and peroxyl free radicals, as well
as nitrogen intermediates (NO and peroxynitrile). The addition of one
electron to dioxygen forms the superoxide anion radical (O•−2) [49].
The production of superoxide occurs mostly within the mitochondria
of a cell [50]. The mitochondrial electron transport chain is the main
source of ATP in themammalian cell and thus is essential for life. During
energy transduction, a small number of electrons “leak” to oxygen pre-
maturely, to generate superoxide, instead of contributing to the reduc-
tion of oxygen to water [51]. Superoxide is produced from both
Complexes I and III of the electron transport chain, and once in its an-
ionic form it is too strongly charged to readily cross the innermitochon-
drial membrane. Recently, it has been demonstrated that Complex I-
dependent superoxide is exclusively released into the matrix and that
no detectable levels escape from intact mitochondria [52]. Under stress
conditions, an excess of superoxide releases free iron from iron-
containingmolecules,which can participate in the Fenton reaction, gen-
erating the highly reactive hydroxyl radical, •OH. Additional reactive
radicals derived from oxygen that can be formed in living systems are
peroxyl radicals (ROO•). The simplest peroxyl radical is HOO•, which is
the protonated form of superoxide (O2•−) and is usually termed either
hydroperoxyl radical or perhydroxyl radical. It is known that hydroper-
oxyl radical initiates fatty acid peroxidation [53]. Superoxide can also
rapidly react with NO in the extracellular space to form peroxynitrite
(ONOO−), which can readily cross cell membranes and damage intra-
cellular components [54].
ROS are produced constantly by aerobic cells through diverse meta-
bolic pathways. They serve as speciﬁc signaling molecules in both, nor-
mal and pathological conditions, and their transient generation, within
boundaries is essential to maintain homeostasis. ROS can inﬂict oxida-
tive molecular damage to lipids, proteins and DNA when their produc-
tion overwhelms the capacity of antioxidant systems [55–57]. The
imbalance is induced by ROS mainly of mitochondrial origin. Biologicaleffects initiated by ROS can elicit a wide range of phenotypic responses
that vary from activation of gene expression, proliferation to growth ar-
rest, and to senescence or cell death [58–60].
1.4. Oxidative stress in neurodegeneration: why it is important
The harmful effects of ROS cause damage tomacromolecules such as
proteins, lipids, polysaccharides or nucleic acids, are termed oxidative
stress. The intrinsic properties of neurons make them highly vulnerable
to the detrimental effects of ROS: high metabolic rates; a rich composi-
tion of fatty acids prone to peroxidation; high intracellular concentra-
tions of transition metals, capable of catalyzing the formation of
reactive hydroxyl radicals; low levels of antioxidants; and reduced capa-
bility to regenerate. Neurons have intense energy demands which are
met by mitochondria. Mitochondria are both targets and important
sources of ROS. It has been shown that oxidative stress stimulates mito-
chondrialﬁssion; the addition of hydrogen peroxide to cultured cerebel-
lar granule neurons induced mitochondrial fragmentation within 1 h of
treatment [61]. It was also shown that nitric oxide causes increased mi-
tochondrial ﬁssion in neurons, prior to the onset of neuronal loss in a
mouse model of stroke [62]. On the other hand, expression of Mfn or a
dominant negative Drp1 in cultured neurons, was protective against ox-
idative insults [61,62]. The generation of ROS appears to be increased in
damaged mitochondria, and in cells with compromised mitochondrial
function. Acute exposure to relatively high levels of ROS, especially in
the presence of calcium, can induce the mitochondrial permeability
transition, uncouple oxidative phosphorylationwith catastrophic effects
on mitochondrial energetics, and contribute to cytotoxicity via necrosis
and/or apoptosis. Oxidative stress within mitochondria can lead to a vi-
cious cycle in which ROS production progressively increases leading, in
turn, to progressive augmentation of damage (Fig. 1).
Nucleic acid oxidation occurs in neurons during disease and is
detected as elevated levels of 8-hydroxy-2-deoxyguanosine (8-
OHDG) in DNA and 8-hydroxyguanosine in RNA. Hydroxyl radical-
mediated DNA damage often results in strand breaks, DNA–protein
crosslinking, and base-modiﬁcations. All of these events can lead to
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tack not only on DNA, but also on other cellular components involving
polyunsaturated fatty acid residues of phospholipids, which are ex-
tremely sensitive to oxidation [63]. Once formed, peroxyl radicals
(ROO•) can be rearranged via a cyclization reaction to endoperoxides
(precursors of malondialdehyde) with the ﬁnal product of the perox-
idation process being malondialdehyde (MDA). The major aldehyde
product of lipid peroxidation other than MDA is 4-hydroxy-2-nonenal
(HNE). Increased production of ROS also results in protein oxidation.
The side chains of all amino acid residues of proteins, in particular
cysteine andmethionine residues of proteins are susceptible to oxida-
tion by the action of ROS/reactive nitrogen species (RNS) [64]. Oxida-
tion of cysteine residues may lead to the reversible formation of
mixed disulﬁdes between protein thiol groups (−SH) and lowmolec-
ular weight thiols, in particular glutathione (GSH, S-glutathiolation).
The concentration of carbonyl groups, generated by many different
mechanisms is a good measure of ROS-mediated protein oxidation.
The generation of isoprostanes has been shown to be a sensitive mea-
sure of lipid peroxidation, which are increased in cerebrospinal ﬂuid
(CSF) of HD patients [65].
Oxidative stress increases with age in the brain and the ability of
cells to respond to oxidative protein damage also declines, contribut-
ing to the build-up of oxidatively damaged proteins. ROS are often
present in brain regions affected by neurodegenerative diseases. In-
creased oxidative alterations to proteins such as α-synuclein in Par-
kinson's disease, β-amyloid in Alzheimer's disease and copper/zinc
superoxide dismutase (SOD1) in Amylotrophic Lateral Sclerosis may
result in increased protein misfolding and impaired degradation,
leading to toxic accumulation of insoluble aggregates in the diseased
brains and an exacerbation of neurodegeneration.
2. Evidence for oxidative damage in HD
Studies in both HD patients and experimental models of HD sup-
port a role for oxidative stress and ensuing mitochondrial dysfunction
in mediating the neuronal degeneration observed in HD. Oxidative
damage in HD has been previously reviewed in detail [34,66–68].
Some of the important and more recent ﬁndings are summarized
below.
2.1. Evidence from HD patients and postmortem studies
Oxidative damage is well documented in plasma of HD patients, HD
postmortem brain tissue, lymphoblasts and cerebrospinal ﬂuid
[34,66,68–71].Markers of oxidative damage, including heme oxygenase
(HO-1, an inducible isoform that occurs in response to oxidative stress),
3-nitrotyrosine (amarker for peroxynitrite-mediatedprotein nitration),
and MDA, are elevated in human HD striatum and cortex as compared
with age-matched control brain specimens [66]. The extent and intensi-
ty of thesemarkersmirror the dorso-ventral pattern of progressive neu-
ronal loss in the neostriatum, with increased immunoreactivity in the
dorsal striatum as compared with the less severely affected ventral stri-
atum. Consistent with the immunohistochemical data, biochemical as-
says in HD patients show signiﬁcant increases in MDA and HNE brain
levels, which are almost 8-fold greater than in control subjects [72].
Chen et al. [73] detected a correlation between lipid peroxidation
products in plasma and degree of severity in patients with HD, and
proposed using them as a potential biomarker for evaluating treat-
ment efﬁcacy. In a recent study, Tunez et al. [74] showed increased
global oxidative stress (GOS), a reduction in antioxidant systems,
and a correlation with disease stage in patients with HD. There is in-
creased cytoplasmic lipofuscin (a product of unsaturated fatty acid
peroxidation) and increased DNA fragmentation in HD patients; the
latter correlated with CAG repeat length [66,75–78]. Aldolase C,
GFAP, tubulin, γ-enolase, and creatine kinase B were found to be
the targets of oxidative modiﬁcation in both striatum and cortexfrom HD patients [70]. More recently, it was shown that the oxidation
of mitochondrial enzymes resulted in decreased catalytic activity in
the striatum samples of HD patients, providing a link to the bioener-
getic deﬁcits observed in HD [79]. These authors also provided evi-
dence that pyridoxal kinase and antiquitin 1 oxidation could result
in decreased pyridoxal 5-phosphate availability, which in turn is nec-
essary as a cofactor in transaminations, synthesis of glutathione, and
synthesis of GABA and dopamine, two neurotransmitters that play a
key role in HD pathology. These ﬁndings suggest that oxidative stress
plays an important role in the pathogenesis of HD.
Additional indirect evidence comes from the studies of Lim et al.
[80] and Tabrizi et al. [81]. Lim et al. [80] investigated dysfunction
of Ca2+ homeostasis in mitochondria from striatal neurons of post-
mortem brains of HD patients. They found that mitochondria in mu-
tant striatal neurons are unable to handle large Ca2+ loads,
possibly due to the increased sensitivity of Ca2+ to the permeability
transition pore opening, which dissipates the membrane potential,
prompting the release of accumulated Ca2+. Harmful ROS, produced
by defective mitochondria, increase in mutant cells, particularly if the
damage to mitochondria is artiﬁcially exacerbated with, for example,
complex II inhibitors. Mitochondria in mutant cells are thus particu-
larly vulnerable to stresses induced by Ca2+ and ROS. The observed
decrease of cell Ca2+ could be a compensatory attempt to prevent
Ca2+ stress that would irreversibly damage mitochondria, and even-
tually lead to cell death. Furthermore, the severe impairment in the
mitochondrial tricarboxylic acid (TCA)-cycle enzyme aconitase in
HD brain, has been attributed to Fe–S clusters within the protein,
which make it a particularly vulnerable target for free radical-
mediated oxidative damage [81]. Aconitase inactivation directly cor-
relates with the generation of superoxide produced by excitotoxicity
[82]. There is evidence for a direct link between glutamate/NMDA
excitotoxicity and aconitase inhibition via NO• and mitochondrial
free radical generation.
2.2. Evidence from experimental models of HD
Many of the oxidative alterations observed in human HD are reca-
pitulated in transgenic and neurotoxin mouse models of HD [34,68].
In mice expressing a N-terminal fragment of HTT exon 1, the R6/2
mice, there are increased concentrations of 8-OHDG in the urine,
plasma, striatal microdialysates, and isolated brain nuclear DNA.
There is increased immunostaining for 8-OHDG and lipid peroxida-
tion markers (MDA, HNE and 8-iso-prostaglandin) in the striatum,
and a progressive increase in the level of mitochondrial DNA damage
in the striatum and cerebral cortex of 7- to 12-week-old R6/2 mice, by
quantitative PCR analysis, and signiﬁcantly increased oxidation of a
number of key cellular proteins, including the metabolic enzymes
creatine kinase, aconitase, neuron-speciﬁc enolase, heat shock pro-
tein 90, and the voltage-dependent anion channel 1, suggesting that
oxidative modiﬁcation of cellular components may contribute to cel-
lular dysfunction, and ultimately to progressive disease [34,83,84]. In
another N-truncated mhtt transgenic model of HD, the N171-82Q
mice, we found evidence of increased oxidative and nitrosative stress
[85]. In full-length knock-in mice, CAG140, 8-OHDG levels are elevat-
ed in brain and urine of the animals [68]. We have also seen enhanced
immunostaining for MDA, 8-OHDG and HNE in the striatum of anoth-
er full length human HD transgenic mouse model, the BACHD mice
(Johri and Beal, unpublished observations, [86]).
It is well known that the administration of the mitochondrial
toxins, 3-nitropropionic acid (3-NP) and malonate, both of which
are selective inhibitors of succinate dehydrogenase, to nonhuman pri-
mates and rodents results in CNS lesions that selectively target
medium-sized spiny neurons within the striatum, recapitulating the
regional and neuronal speciﬁcity of pathologic events in HD. In
these toxins and in the excitotoxin models of HD, increased oxidative
damage has been consistently observed [34].
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The accumulation of ROS in neurons, and subsequent oxidative
stress are attenuated by free radical scavengers, which can be catego-
rized as enzymatic or non-enzymatic antioxidants. Enzymatic antiox-
idants constitute one of the defense mechanisms against free radicals.
These include superoxide dismutase (SOD), glutathione peroxidase
(Gpx) and catalase (CAT). Non-enzymatic antioxidants are repre-
sented by ascorbic acid (Vitamin C), α-tocopherol (Vitamin E), gluta-
thione (GSH), retinoic acid, carotenoids, ﬂavonoids, and other
antioxidants. The therapeutic approaches tested in vitro, or in toxin
or transgenic models of HD and trials in HD patients are summarized
below and in Table 1.
3.1. In vitro studies
3.1.1. Metalloporphyrins
Metalloporphyrins, metal-containing catalytic antioxidants, have
emerged as a novel class of potential therapeutic agents that scavenge
a wide range of reactive oxygen species. A manganese porphyrin has
been reported to signiﬁcantly reduce cell death in an in vitro chemical
model of HD [87].
3.1.2. Ascorbic acid (Vitamin C)
Ascorbic acid (Vitamin C) is a potent antioxidant obtained exoge-
nously, which oxidizes readily to dehydroxyascorbic acid in the pres-
ence of reactive oxygen species. Treating cultured rodent cortical
neurons with glutamate resulted in signiﬁcant neurodegeneration,
which was completely rescued with ascorbic acid co-treatment [88].
3.1.3. α-Tocopherol (Vitamin E)
α-Tocopherol (Vitamin E) is also a potent antioxidant. Using a
neuronal cell-based assay, glutamate-induced neuronal death was
signiﬁcantly attenuated in a dose-dependent manner by α-
tocopherol [89]. Also, treatment with idebenone in this in vitro
model resulted in complete neuroprotection in a dose-dependent
manner [89].
3.1.4. Grape seed phenolic extract (GSPE)
More recently, Wang et al. [90] demonstrated that Grape seed
phenolic extract (GSPE) inhibited mhtt aggregation in PC-12 cells
expressing 103 glutamines fused with enhanced GFP (Htt103Q-
EGFP), and reduced the carbonyl levels induced by the expression of
mhtt protein. GSPE is a strong antioxidant and powerful metal chela-
tor that can effectively reduce ROS in vivo and has been shown to at-
tenuate spatial memory impairment in a mouse model of AD [91].
3.2. In chemically induced rodent and murine models of HD
3.2.1. Melatonin
Melatonin, which is an excellent scavenger of hydroxyl, carbonate,
reactive nitrogen species, and other organic radicals, has demonstrat-
ed signiﬁcant neuroprotection in the kainic acid rodent model of neu-
rodegeneration [92]. Melatonin signiﬁcantly reduced DNA damage
and improved neuronal survival. In another study using the 3-NP
model of HD, melatonin treatment signiﬁcantly ameliorated the in-
crease in lipid peroxidation, protein carbonyls and SOD activity with-
in the striatum [93].
3.2.2. Selenium
Selenium, is an essential element required by glutathione peroxi-
dase to form the active enzyme. Selenium dose-dependently reduced
lipid peroxidation and signiﬁcantly improved neuronal morphology
within the striatum of rats treated with quinolinic acid, an N-methyl-
D-aspartate antagonist that results in striatal neurodegeneration [94].
There was a signiﬁcant improvement in striatal GABA concentrationsand signiﬁcant improvements in behavior, including a reduction in
ipsilateral turning, in these animals as compared with untreated
controls.
3.2.3. Pyruvate
Using a quinolinic acid striatal lesion model of HD, treatment with
pyruvate dose-dependently protected against striatal neurodegen-
eration [95]. Although lower doses provided no protection, relatively
higher doses provided signiﬁcant neuroprotection, reducing the stria-
tal lesion area relative to controls.
3.2.4. Idebenone
Idebenone, a benzoquinone derivative, possesses a potent antiox-
idant capacity and readily penetrates the brain. Intrastriatal injection
of kainic acid into the rat striatum resulted in a marked reduction in
the presynaptic striatal marker glutamic acid decarboxylase (GAD).
Treatment with idebenone resulted in a signiﬁcant, nearly complete
restoration of GAD immunoreactivity [96]. However, idebenone had
no effect on decreases of GAD immunoreactivity induced by quinoli-
nic acid striatal lesions in these studies.
3.2.5. Tauroursodeoxycholic acid (TUDCA)
Tauroursodeoxycholic acid (TUDCA) is a hydrophilic bile acid with
antioxidant properties. TUDCA prevented striatal degeneration and
ameliorated locomotor and cognitive deﬁcits in a 3-NP rat model of
HD [97].
3.2.6. N-acetylcysteine (NAC)
Treatment of rats with N-acetylcysteine (NAC), a known glutathi-
one precursor, before 3-NP treatment, protected against oxidative
damage induced by 3-NP as measured by electron paramagnetic res-
onance (EPR) and western blot analysis for protein carbonyls [98].
Furthermore, NAC treatment before 3-NP administration signiﬁcantly
reduced striatal lesion volumes. The authors suggested that oxidative
damage is a prerequisite for striatal lesion formation and that antiox-
idant treatment may be a useful therapeutic strategy against 3-NP
neurotoxicity and perhaps against HD as well [98].
3.2.7. Creatine
Creatine is a naturally occurring compound that has been shown to
act as an antioxidant [99]. Creatine also buffers intracellular energy re-
serves through its intermediate, phosphocreatine (PCr); stabilizes in-
tracellular calcium; and inhibits activation of the mitochondrial
transition pore [100]. Creatine supplementation signiﬁcantly reduces
striatal lesion volumes produced by the neurotoxins 3-NP andmalonate
[101,102].
3.2.8. CoQ10
The antioxidant compound CoQ10 also demonstrated efﬁcacy in
murine models of HD. CoQ10, ubiquinone, is a lipid-soluble benzoqui-
none which, when reduced to ubiquinol, possesses a signiﬁcant anti-
oxidant potential. In addition, CoQ10 can induce increases in Vitamin
E, enhancing its antioxidant capacity. Using the mitochondrial toxins
malonate and 3-NP, treatment with CoQ10 resulted in dose-
dependent neuroprotection, with signiﬁcant CoQ10-mediated reduc-
tions in striatal lesion volume [103,104].
3.2.9. CoQ10 and creatine
CoQ10 and creatine have additive effects on bioenergetics. We ex-
amined the effects of combined treatment of CoQ10 with creatine in
the 3-NP model of HD [105]. The combination diet exerted signiﬁcant
additive neuroprotective effects in blocking the 3-NP-incuded striatal
lesions, preserving striatal GSH levels and the ratio of GSH/GSSG, and
in reducing the striatal MDA levels and 8-OHDG levels in the cerebral
cortex of 3-NP treated rats [105].
Table 1
Summary of antioxidants studies in HD.
Antioxidants Site/mechanism of antioxidant action In HD
patients
In
transgenic
HD mice
In chemically
induced animal
models of HD
References
α-tocopherol
(Vitamin E)
A lipid soluble antioxidant; protects cell membranes from oxidation; acts
via glutathione peroxidase pathway
+,+ nd +,+ +,− (in
combination
with CoQ10)
[123,133,134]
Creatine Major role in intracellular energy buffering in conjunction with
phosphocreatine; effective against superoxide, peroxynitrite and hydroxyl
radicals
+,+, fsp +,+ +,+ [125,126,116,117,101,102]
CoQ10 Present on inner mitochondrial membrane, functions as electron carrier in
ETC and effectively reduces singlet oxygen; prevents oxidation of bases in
mitochondria and formation of lipid peroxyl radicals and protein oxidation
in lipid membranes
+,+, fsp +,+ +,+ [68,127,118,103,104]
CoQ10+Creatine A combination of CoQ10 and creatine is expected to have additive effects
on bioenergetics and act as powerful antioxidants
nd +,+ +,+ [105]
Idebenone A synthetic analog of CoQ10, has antioxidant properties similar to CoQ10;
recently shown to be a substrate of NAD(P)H:quinone oxidoreductase
(NQO)-1 and 2
+,−, nsp nd +,+ [124,96]
L-carnitine Biologically active enantiomer of carnitine, involved in transport of fatty
acids into mitochondria for production of energy; protects against lipid
peroxidation of membranes
+,nsp (L-
acetyl
carnitine)
+,+ nd [135,119]
Lipoic acid An essential cofactor of mitochondrial enzyme complexes; catalyzes
oxidative decarboxylation of pyruvate; has the ability to scavenge reactive
oxygen and reactive nitrogen species (ROS/RNS), chelate metals, also
called ‘antioxidant of antioxidants’
nd +,+ nd [111]
Apocynin An inhibitor of NADPH oxidase activity which reduces molecular oxygen to
a superoxide radical
nd nd +,+ [136]
BN82451 A hybrid multi-targeting molecule designed as a neuroprotective disease
modifying agent; reduces excitotoxicity, oxidative stress, and inﬂamma-
tion, and is also a mitochondrial protective agent
nd +,+ nd [113]
FK-506 An immunosuppressive drug, a potent calcineurin (protein phosphatase
2B) inhibitor, has anti-inﬂammatory and anti-oxidant {modulation of nitric
oxide synthase (NOS) and HO activities} properties
nd nd +,+ [106]
Grape seed phenolic
extract (GSPE)
GSPE has high concentrations of Vitamin E, ﬂavonoids, linoleic acid,
polyphenols, such as resveratrol; limits lipid peroxidation and reduces
inﬂammation
nd +,+ nd [90]
Kynurenine-3-
monooxygenase
(KMO) inhibitors
Inhibition of KMO in blood increases kynurenic acid in brain and reduces
extracellular glutamate and free radical production
nd +,+ nd [122]
Lycopene A phytochemical, found in red fruits and vegetables, exerts antioxidant
effects by quenching singlet oxygen
nd nd +,+ [107]
Melatonin Produced in the body by pineal gland, acts as a synchronizer of biological
clock and also possesses a strong antioxidant activity by scavenging ROS/
RNS and inhibiting NOS. Protects lipids in membranes, proteins in cytosol,
DNA in nucleus and mitochondria from free radical damage
nd nd +,+ [92,93]
N-acetylcysteine (NAC) A pharmaceutical drug and nutritional supplement, reduces oxidative
stress by reducing ROS and lipid peroxidation and restoration of
antioxidant enzymes.
nd nd +,+ [98]
Nordihydroguaiaretic
acid (NDGA)
NDGA is a lignan found in leaves and twigs of the shrub Larrea tridentate,
prevents lipid peroxidation and 4-hydroxynonenal adduct formation
nd +,+ nd [137]
Olive oil Obtained from Olea europea, contains high levels of polyphenol
antioxidants, CoQ10 and melatonin; displays antimicrobial, antioxidant
and anti-inﬂammatory properties
nd nd +,+ [138]
Pyruvate The carboxylate anion of pyruvic acid, is an important mediator in several
metabolic pathways; acts by restoration of the glutathione antioxidant
ratio, also shown to prevent lipid peroxidation and oxidative DNA damage
nd +,+ +,+ [112,95,139]
Selenium An essential biological trace element; biological effects are mainly due to
the antioxidant function of selenoproteins, which help maintain the
intracellular redox status and prevent cellular damage from free radicals
nd nd +,+ [94]
Synthetic triterpenoids Triterpenoids (TPs), particularly those which are analogs of 2-Cyano-3,12-
Dioxooleana-1,9-Dien-28-oic acid (CDDO), have antioxidant and anti-
inﬂammatory properties; act via Nrf2/ARE pathway
nd +,+ +,+ [85,108]
Tauroursodeoxycholic
acid (TUDCA)
A hydrophilic bile acid, has anti-inﬂammatory and cytoprotective effects;
also has antioxidant effects, mechanism of action not fully deﬁned yet;
known to act through protein kinase C/A
nd +,+ +,+ [114,97]
Withania somnifera root
extract
Contains alkaloids and steroidal lactones; shown to induce the expression
of antioxidant enzymes and reduce oxidative stress markers
nd nd +,+ [140]
+,+=tested, beneﬁcial effects.
+,−=tested, no beneﬁcial effects.
nd=not determined.
nsp=not sufﬁcient power.
fsp=further studies in progress.
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FK-506 is an immunosuppressive drug mainly used to lower allo-
graft rejection and also in topical preparations. Recently, the neuro-
protective effects of FK-506 were reported in the 3-NP model of HD
[106]. FK-506 treatment signiﬁcantly reduced behavioral deﬁcits,
MDA levels, nitrite concentration, and restored antioxidant enzyme
levels of SOD and catalase, and levels of dopamine and norepineph-
rine in the striatum, cortex, and hippocampus.
3.2.11. Lycopene
Lycopene, a carotenoid pigment and phytochemical naturally
found in fruits and vegetables, reduced oxidative stress markers and
improved behavior in a 3-NP induced rodent model of HD [107].
3.2.12. The synthetic triterpenoid, CDDO-methyl amide
The synthetic triterpenoid, CDDO-methyl amide (2-cyano-N-
methyl-3,12-dioxooleana-1,9(11)-dien-28 amide; CDDO-MA), acti-
vates the Nrf-2/ARE pathway resulting in induction of NAD(P)H de-
hydrogenase (quinone) 1 (NQO-1), and suppression of inducible
nitric oxide synthase (iNOS). This compound is several times more
potent than its naturally occurring distant parent, oleanolic acid.
CDDO-MA treatment signiﬁcantly attenuated 3-NP induced loss of
striatal NeuN stained neurons, blocked the depletion of striatal GSH,
preserved the ratio of GSH/GSSG and reduced MDA levels in the stri-
atum and cerebral cortex of 3-NP treated rats, providing evidence
that blocking oxidative stress by inducing the Nrf-2/ARE pathway
may be an effective therapeutic approach for treatment of HD [108].
3.3. In transgenic mouse models of HD
3.3.1. Lipoic acid
Lipoic acid is an essential cofactor for many enzyme complexes and
is present in mitochondria as the cofactor for pyruvate dehydrogenase
and alpha-ketoglutarate dehydrogenase. It is an effective antioxidant
and has been used to treat disease associatedwith impaired energyme-
tabolism [109]. It also induces the Nrf-2/ARE pathway [110]. In both the
R6/2 and N171-82Q transgenic mouse models of HD, dietary supple-
mentation with lipoic acid resulted in signiﬁcant extension of survival,
and delayed weight loss in N171-82Q transgenic mice [111].
3.3.2. Pyruvate
Pyruvate plays a major role in glycolysis, and also possesses signif-
icant antioxidant capacity. Treatment with dichloroacetate, which
stimulates pyruvate dehydrogenase, improved the HD phenotype of
both R6/2 and N171-82Q mice, suggesting that, in addition to its
antioxidant capacity, pyruvate may promote neuroprotection by
improving energetic potential [112].
3.3.3. BN82451
BN82451 is a brain-permeable compound that exerts neuroprotec-
tive effects, including the inhibition of lipid peroxidation. Administra-
tion of BN82451 in R6/2 mice resulted in a signiﬁcant extension of
survival, signiﬁcant improvements in motor function, with improve-
ments in gross morphology, striatal volume, and striatal neuronal
areas, and a signiﬁcant decrease in the number of ubiquitin positive ag-
gregates in R6/2 mice as compared with untreated control mice [113].
3.3.4. TUDCA
TUDCA prevents the production of reactive oxygen species, miti-
gates mitochondrial insufﬁciency and apoptosis, in part, by inhibiting
Bax translocation from cytosol to the mitochondria. Keene et al. [114]
showed that systemically administered TUDCA signiﬁcantly reduced
striatal neuropathology, decreased striatal apoptosis, reduced the
size of ubiquitinated neuronal intranuclear htt inclusions and im-
proved locomotor and sensorimotor deﬁcits in the R6/2 transgenic
HD mouse.3.3.5. Creatine
Creatine exists in the cell both as free creatine and phosphocrea-
tine (PCr) which together comprise the total creatine pool. In tissues
with high energy requirements such as skeletal muscle and brain,
PCr serves as a short term energy buffer in which adenosine diphos-
phate is phosphorylated to adenosine triphosphate. This phosphor-
ogroup transfer is catalyzed by the important creatine kinase (CK)
enzyme [115]. Creatine supplementation in the R6/2 and the N171-
82Q transgenic mouse models produced an improvement in motor
performance, extended survival, attenuated the loss of body weight
and brain weight and reduced neuronal atrophy [116,117].
3.3.6. CoQ10
Located in the inner mitochondrial membrane, CoQ10 is essential
for complex I and II electron transfer activities during oxidative phos-
phorylation, and plays a vital role in ATP production. Treatment with
CoQ10 signiﬁcantly increases levels of mitochondrial CoQ10 in the
brain [104]. We showed that CoQ10 administration signiﬁcantly at-
tenuates brain weight loss, gross brain atrophy, ventricular enlarge-
ment, striatal neuron atrophy, extends survival, and improves motor
performance in R6/2 mice [118].
We showed the additive neuroprotective effects of CoQ10 and cre-
atine in improving motor performance, survival and striatal atrophy
in the R6/2 transgenic mouse model of HD, providing evidence that
the combination has improved efﬁcacy as compared with either com-
pound alone [105].
3.3.7. L-carnitine
L-carnitine (4-N-trimethylammonium-3-hydroxy-butyric acid)
plays a role in the control of the mitochondrial acyl-coenzyme A/co-
enzyme A ratio, peroxisomal oxidation of fatty acids, and also acts
as a free-radical scavenger. It is effective in preventing cell membrane
damage caused by reactive oxygen species. Recently, administration
of a relatively high dose of L-carnitine to N171-82Q transgenic mice
was shown to extend the survival, ameliorate motor performance,
and decrease the number of intranuclear mhtt aggregates [119].
3.3.8. Grape seed phenolic extract (GSPE)
Grape seed phenolic extract (GSPE) treatment in both ﬂy and R6/2
mouse models of HD effectively extended lifespan in both models,
and reduced motor deﬁcits in the R6/2 mice, demonstrating preclini-
cal efﬁcacy of GSPE in HD treatment [90].
3.3.9. Synthetic triterpenoids
Synthetic triterpenoids, which are analogs of 2-Cyano-3,12-
Dioxooleana-1,9-Dien-28-Oic acid (CDDO), are of great interest be-
cause of their antioxidant and anti-inﬂammatory properties. We re-
cently showed that administration of triterpenoids, which activate
the Nrf-2/ARE transcriptional pathways, are neuroprotective in the
N171-82Q transgenic mouse model of HD [85]. Triterpenoids signiﬁ-
cantly preserved the striatal volumes of the N171-82Q mice, by pre-
venting the atrophy of the medium spiny neurons, and they rescued
behavioral deﬁcits, extended survival, attenuated peripheral patholo-
gy, and reduced 8-OHDG, MDA and 3-nitrotyrosine immunoreactivity
in the striatum [85]. We used two derivatives in this study, CDDO-EA
and CDDO-TFEA, which have better brain penetration than the previ-
ously used derivative (CDDO-MA), and therefore have great promise
from a therapeutic standpoint for disorders of the central nervous
system.
3.3.10. Kynurenine-3-monooxygenase inhibitors
Metabolites of the kynurenine pathway of tryptophan metabolism
include kynurenic acid, which is a broad spectrum inhibitor of excit-
atory amino acid receptors. Both we and others showed that there
are marked decreases of kynurenic acid levels in HD postmortem
brain tissue [120]. Both glutamate-mediated excitotoxicity and free
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tions. Recently, the administration of kynurenic acid was shown to
block neurodegeneration in a Drosophila model of HD [121]. Further-
more, the oral administration of JM6, an inhibitor of kynurenine-3-
monooxygenase, which does not cross into the brain, was shown to
increase kynurenic acid levels and reduce extracellular glutamate in
the brain [122]. Chronic administration of JM6 extended life span,
prevented synaptic loss and decreased microglial activation in the
R6/2 transgenic mouse model of HD [122].3.4. Clinical trials in HD patients
Successful preliminary demonstration of α-tocopherol to limit ox-
idative damage and neurodegeneration led to a clinical assessment of
its potential in human HD [123]. A year-long placebo-controlled,
double-blind study was carried out in patients with mild to moderate
HD symptoms. Although α-tocopherol had no effect on neurologic or
neuropsychiatric symptoms in the treatment group overall, post hoc
analysis showed a signiﬁcant effect on neurologic symptoms in HD
patients early in the course of the disease. Peyser and colleagues
[123] concluded that α-tocopherol therapy may slow the rate of
motor decline early in the course of HD.
As a result of the positive in vitro and in vivo studies (Sections 3.1
and 3.2 above), a double-blind, placebo-controlled trial of idebenone
in 92 HD patients was performed [124]. A clinical trial with idebenone
had no effect on primary outcome measures when compared with
placebo controls. This trial, however, was not sufﬁciently powered
to detect a signiﬁcant drug effect, other than a complete cessation of
disease progression, more subtle beneﬁcial effects of idebenone may
have been present and have been undetected, and therefore require
further multicenter trials.
Due to the beneﬁcial effects of creatine supplementation in our
neurotoxin HD and transgenic mouse HD models (Sections 3.2 and
3.3 above), we carried out a 16-week, randomized double-blind pla-
cebo control phase II clinical trial on the safety and tolerability of
8 g per day of creatine in HD patients [125]. This study illustrated
that creatine supplementation signiﬁcantly reduced elevated serum
levels of 8-OHDG back to baseline levels seen in controls. An open-
label add-on study of creatine showed further beneﬁts in HD
patients. In particular, there was a slowing of the ongoing cortical
atrophy. It was also shown that higher doses as high as 30 g daily
exerted clinical beneﬁts in the HD patients [126]. In view of this, a
double blind placebo controlled phase III clinical trial has been
approved and is currently ongoing at a large number of centers,
which are part of the Huntington Study Group. In this clinical trial,
patients will be titrated up to the maximum tolerated dose, and
then they will be assessed utilizing the United Huntington Disease
Rating Scale (UHDRS) as well as on quality of life scales, cognition
and a variety of other measures.
Based on favorable preclinical CoQ10 efﬁcacy, several human
safety and tolerability trials have been conducted using CoQ10
[68]. In each trial, CoQ10 was found to be safe and tolerable. A mul-
ticenter clinical trial (CARE-HD) of CoQ10 (600 mg/day) found a
trend toward slowing in total functional capacity decline over
30 months, a signiﬁcant slowing in decline on the independence
scale, and a signiﬁcant beneﬁcial effect on measures of cognitive
function. Because the single target dose did not signiﬁcantly affect
the speciﬁed primary outcome of the trial, a higher CoQ10 dose
study is underway, to investigate whether it will provide greater
efﬁcacy in HD patients. This dosage-escalation trial of CoQ10
demonstrated that higher dosages of this compound appear to be
generally safe in subjects with HD and in healthy controls [127].
The present phase III trial of the Huntington Study Group is
testing CoQ at a dosage of 2400 mg/day in 608 patients over
60 months.4. Future perspectives: mitochondrial medicine
Oxidative stress and mitochondrial dysfunction in HD are inter-
twined and as such, blocking one should improve the other. Many
of the therapeutic compounds described in the Section 3 above, not
only block the oxidative stress, but also improve mitochondrial func-
tion in HD. “Mitochondrial medicine” describes efforts to directly
manage mitochondrial dysfunction as well as attempts to directly or
indirectly manage its consequences, such as reducing oxidative stress
or blocking the mitochondrial integration with programmed cell
death. Traditional attempts to enhance mitochondrial function or
block mitochondrial dysfunction have included therapies with vita-
mins or such co factors that generate bioenergetic pathway interme-
diates or feed electrons to the respiratory chain. Mitochondria-
targeted antioxidants may enhance the therapeutic beneﬁts of such
therapy.
Another important therapeutic approach is to improve the func-
tion of PGC-1α in HD. PGC-1α, the master co-regulator of energy
metabolism also plays a role in the suppression of oxidative stress.
PGC-1α induces mitochondrial uncoupling proteins and antioxidant
enzymes, including SOD1, manganese SOD (SOD2), and Gpx-1
[128]. There is substantial evidence for impairment of PGC-1α levels
and activity in HD [41–46]. PGC-1α knockout mice exhibit mitochon-
drial dysfunction, defective bioenergetics, a hyperkinetic movement
disorder and striatal degeneration, which are features also observed
in HD [129,130]. Selective ablation of PGC-1α leads to increased stria-
tal neuron degeneration, and increased susceptibility to the mito-
chondrial toxin 3-NP in HD transgenic mice [41]. In concert with the
decreased expression and impaired function of PGC-1α, antioxidant
systems are impaired. Therefore, therapeutic approaches targeting
PGC-1α may be beneﬁcial both in improving mitochondrial function
and biogenesis as well as in restoring the expression of antioxidant
enzymes and ameliorating oxidative damage in HD. One such com-
pound is bezaﬁbrate, which is a pan-PPAR agonist, which increases
expression of PGC-1α, and has shown efﬁcacy in reducing oxidative
damage, and improving behavioral deﬁcits, survival, and striatal atro-
phy in a transgenic mouse model of HD [Johri and Beal, unpublished
observations]. A number of other agents including pioglitazone, a
PPAR-γ agonist, and thiazolidinedione also show efﬁcacy in exerting
neuroprotective effects against mutant htt toxicity both in vitro and
in vivo [131,132]. Agents which can transcriptionally activate the
Nrf-2/ARE pathway, leading to increased expression of antioxidant
enzymes, and chaperone proteins, as well as reduce the production
of oxidants by iNOS and cyclooxygenase-2, are also promising agents
for neuroprotection in HD [85]. An advantage of these approaches is
that they modulate endogenous neuroprotective pathways, and that
they involve catalytic processes which are not consumed but are re-
generative, allowing ongoing antioxidant effects. Mitochondrial med-
icine and transcriptional modulation of antioxidant pathways
therefore hold great promise for the development of neuroprotective
therapies to ameliorate or halt the progression of HD.
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